Mankind Pharma News and Updates

Pharmaceuticals company Mankind Pharma announced Q3FY24 & 9MFY24 results: Q3FY24: Revenue from Operations at Rs 2,607 crore, 25% YoY growth Domestic revenue at Rs 2,400 crore, 20% YoY growth Export revenue at Rs 207 crore, 118% YoY growth EBITDA at Rs 611 crore, 39% YoY growth with a margin of 23.4% (up 240 bps YoY) PAT at Rs 460 crore, 55% YoY growth with a margin of 17.6% (up 350 bps YoY) Diluted EPS of Rs 11.3, 59% YoY growth (FV Re 1) 9MFY24: Revenue from Operations at Rs 7,894 crore, 18% YoY growth Domestic revenue at Rs 7,348 crore, 13% YoY growth Export revenue at Rs 546 crore, 154% YoY growth EBITDA at Rs 1,957 crore, 31% YoY growth with a margin of 24.8% (up 250 bps YoY) PAT at Rs 1,465 crore, 44% YoY growth with a margin of 18.6% (up 340 bps YoY) Diluted EPS of Rs 35.9, 44% YoY growth (FV Re 1) Cash flow from operations of Rs 1,636 crore, 23% YoY growth Net cash balance of Rs 2,756 crore as of 31st December 2023 Rajeev Juneja, Vice Chairman & Managing Director, Mankind Pharma, said, “We are delighted to announce strong Q3 results with Domestic Growth of 20% YoY led by robust growth in Chronic, recovery in anti-infectives, and strong growth in modern trade and hospital sales. Our top 5 therapeutics by sales have outperformed the IPM by 1.5x. We have increased our market share in 18 out of the top 20 brands on both QoQ and YoY basis. These have resulted in a robust EBITDA growth of 39% YoY and PAT growth of 55% YoY in Q3. We continue to focus on improving cash flow from operations and optimising our working capital cycle.” Result PDF

27.01% Fall from 52W High

Mankind Pharma News and Updates

Keep track of all breaking news on Mankind Pharma from all sources in a single place.